Basic & clinical pharmacology & toxicology | 2021

Methylophiopogonanone A is a naturally occurring broad-spectrum inhibitor against human UDP-glucuronosyltransferases: inhibition behaviours and implication in herb-drug interactions.

 
 
 
 
 
 
 
 
 
 

Abstract


Methylophiopogonanone A (MOA) is an abundant homoisoflavonoid in the Chinese herb Ophiopogonis Radix. Recent investigations revealed that MOA inhibited several human cytochrome P450 enzymes (CYPs) and stimulated OATP1B1. However, the inhibitory effects of MOA on phase II drug-metabolizing enzymes, such as human UDP-glucuronosyltransferases (hUGTs), have not been well investigated. Herein, the inhibition potentials of MOA on hUGTs were assessed. The results clearly demonstrated that MOA dose-dependently inhibited all tested hUGTs including UGT1A1 (IC50 = 1.23 μM), one of the most important detoxification enzymes in humans. Further investigations showed that MOA strongly inhibited UGT1A1-catalyzed NHPH-O-glucuronidation in a range of biological settings including hUGT1A1, human liver microsomes (HLM) and HeLa cells overexpressing UGT1A1. Inhibition kinetic analyses demonstrated that MOA competitively inhibited UGT1A1-catalyzed NHPH-O-glucuronidation in both hUGT1A1 and HLM, with Ki values of 0.52 μM and 1.22 μM, respectively. In addition, the potential risks of MOA-associated herb-drug interactions (HDIs) via inhibiting hUGT1A1 were predicted by utilizing in vitro inhibition constants and the plasma exposure of the agent. Collectively, our findings expanded knowledge of the interactions between MOA and human drug-metabolizing enzymes, which would be very helpful for guiding the use of MOA-related herbal products in clinical settings.

Volume None
Pages None
DOI 10.1111/bcpt.13651
Language English
Journal Basic & clinical pharmacology & toxicology

Full Text